AllerWAVE: A Photonic Leap in Drug Allergy Diagnostics

By 2050, antimicrobial resistance (AMR) is projected to cause 10 million deaths annually, surpassing cancer as the leading cause of death worldwide, according to the UN’s Bracing for Superbugs report. AMR represents a global health emergency—threatening not only infectious disease treatment but also routine surgeries, cancer care, and organ transplants, all of which depend on effective antibiotics.

One key, often overlooked driver of AMR is the mislabeling of antibiotic allergies, especially to penicillin. An estimated 90% of patients labeled as allergic to first-line antibiotics are not truly allergic. Yet these labels persist, leading clinicians to prescribe second-line, broad-spectrum antibiotics that are more expensive, less effective, and significantly more likely to promote resistance.

A technology born to protect antibiotics

At Bioherent, we are responding to this challenge with AllerWAVE^TM—a diagnostic test that brings unprecedented accuracy, accesibility and speed to antibiotic allergy diagnostics.

Our technology detects allergic responses with high sensitivity using integrated photonic biosensing, minimizing false results and enabling personalized, evidence-based antibiotic prescribing. By identifying who is truly allergic, and who is not, we help clinicians safely prescribe first-line antibiotics, avoiding unnecessary switches to broader agents not always available.

Why this matters in the fight against AMR

Every misdiagnosed allergy leads to broader-spectrum antibiotic use. This misuse creates ideal conditions for drug-resistant bacteria to emerge and spread. Compounding the crisis is the lack of incentives for developing new antibiotics—which means preserving the effectiveness of existing ones is more critical than ever. Addressing antibiotic allergy mislabeling is a strategic, cost-effective intervention in the global AMR response—and a key focus of the Antimicrobial Resistance Fighter Coalition.

Source:

Antimicrobial Resistance Fighter Coalition (2023). Bracing for Superbugs Report.